In recent years there have been exciting developments in the diagnosis and treatment of mild cognitive impairment and dementia due to Alzheimer's disease. Robust biomarkers and potentially disease modifying therapies are now available, with multiple other agents in clinical trials alongside on-going validation studies of blood-based biomarkers. Recent and probable future developments in the diagnosis and care of people with Alzheimer's disease pathology warrants serious re-evaluation of the structure and function of cognitive clinical services. Here we report recommendations from the November 2024 Brain Health Scotland roundtable discussion of opportunities and challenges for modern memory services.
BarkerWWLuisCAKashubaA, et al.Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida brain bank. Alzheimer Dis Assoc Disord2002; 16: 203–212.
4.
De ReuckJDeramecourtVCordonnierC, et al.The incidence of post-mortem neurodegenerative and cerebrovascular pathology in mixed dementia. J Neurol Sci2016; 366: 164–166.
5.
BennettDABuchmanASBoylePA, et al.Religious orders study and rush memory and aging project. J Alzheimers Dis2018; 64: S161–S189.
6.
RahimiJKovacsGG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther2014; 6: 82–82.
7.
BoylePYuLWilsonR, et al.Relation of neuropathology with cognitive decline among older persons without dementia. Front Aging Neurosci2013; 5: 50–50.
8.
GaoYLiuYLiY. Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: a systematic review and meta-analysis. Adv Clin Exp Med2024; 33: 1179–1187.
9.
van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer's disease. N Engl J Med2023; 388: 9–21.
10.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
CummingsJLZhouYLeeG, et al.Alzheimer's disease drug development pipeline: 2025. Alzheimers Dement (N Y)2025; 11: e70098.
17.
HsuCWHsuTWKaoYC, et al.The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis. J Prev Alzheimers Dis2025; 12: 100195.
18.
SchottJMMarshallCR. Amyloid immunotherapy for Alzheimer's disease: the case for cautious adoption. Arq Neuropsiquiatr2025; 83: 1–4.
19.
WillisBPennerNRawalS, et al.Subcutaneous (SC) lecanemab is predicted to achievecomparable efficacy and improved safety compared tolecanemab IV in early Alzheimer’s disease (AD). Alzheimers Dement2023; 19: e082852.
20.
MuirRTHillMDBlackSE, et al.Minimal clinically important difference in Alzheimer's disease: rapid review. Alzheimers Dement2024; 20: 3352–3363.
21.
Eisai. Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference. https://www.eisai.com/news/2024/news202481.html (2024).
22.
van DyckCHSperlingRJohnsonK, et al.Long-term safety and efficacy of lecanemab in early Alzheimer's disease: results from the clarity AD open-label extension study. Alzheimers Dement2025; 21: e70905.
23.
ShcherbininSGueorguievaIChengY, et al.Amyloid re-accumulation after donanemab treatment: summary from 3 interventional trials. Alzheimers Dement2023; 19: e078175.
24.
JagustWJ. Landau SM and Alzheimer's disease neuroimaging initiative. Temporal dynamics of beta-amyloid accumulation in aging and Alzheimer disease. Neurology2021; 96: e1347–e1357.
25.
SimsJR. Donanemab in early symptomatic Alzheimer’s disease: efficacy and safety from the TRAILBLAZER-ALZ 2 long-term extension. Toronto, Canada: Alzheimer's Association International Conference (AAIC), 2025.
ClausJJVom HofeIvan Ijlzinga VeenstraA, et al.Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer's disease to individuals with mild cognitive impairment or early Alzheimer's disease in the general population. Eur J Epidemiol2025; 40: 327–337.
28.
HonigLSBarakosJDhaddaS, et al.ARIA In patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. Alzheimers Dement (N Y)2023; 9: e12377.
29.
WangHNeryESMArdayfioP, et al.The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6. J Prev Alzheimers Dis2025; 12: 100266.
30.
Healthcare Quality Improvement Partnership. Royal College of Psychiatrists (2023/24) National Audit of Dementia Spotlight Audit in Memory Assessment Services national report. 2024.
DunneRAAarslandDO'BrienJT, et al.Mild cognitive impairment: the Manchester consensus. Age Ageing2021; 50: 72–80.
33.
AskenBMCidRECCroccoEA, et al.Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217. J Prev Alzheimers Dis2025; 12: 100011.
CullenNCLeuzyAJanelidzeS, et al.Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun2021; 12: 3555.
36.
HanssonOBlennowKZetterbergH, et al.Blood biomarkers for Alzheimer's disease in clinical practice and trials. Nat Aging2023; 3: 506–519. 20230518.
37.
LaurellAASVenkataramanAVSchmidtT, et al.Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK. Br J Psychiatry2024; 224: 198–204.
38.
DobsonRPattersonKMalikR, et al.Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease. J Neurol Neurosurg Psychiatry2024; 95: 796–803.
39.
RichMBBlout ZawatskyCLBottaJJ, et al.Public perspective on medications to delay Alzheimer's disease symptoms. J Genet Couns2023; 32: 1009–1017.
40.
UnderwoodBR. Predicting how many people might receive treatment with new therapies for Alzheimer's disease. J Neurol Neurosurg Psychiatry2024; 95: 793.
41.
LeroiIPeelCDavenportR, et al.Blueprint for a brain health clinic to detect and manage early-stage cognitive decline: a consensus exercise. J Neurodegener Disord2020; 3: 54–64.
42.
RitchieCWRussTCBanerjeeS, et al.The Edinburgh consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. Alzheimers Res Ther2017; 9: 85.
43.
MacEwanTBettsPBlackK, et al.Brain Health Scotland (BHS) - a pioneering brain health service in Aberdeen, Scotland. BJPsych Open2025; 11: S11.
44.
RabinoviciGDRafiiMSApgarC, et al.ALZ-NET: using real world evidence to inform the future of Alzheimer’s treatment and care. Alzheimers Dement2022; 18: e069542.
45.
PerneczkyRDarbyDFrisoniGB, et al.Real-world datasets for the international registry for Alzheimer's disease and other dementias (InRAD) and other registries: an international consensus. J Prev Alzheimers Dis2025; 12: 100096.
46.
Luengo-FernandezRLealJGrayA. UK Research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia. BMJ Open2015; 5: e006648.
